The ELEGANT trial enrolls all high-risk ER-positive patients, not just those with ESR1 mutations. The rationale is that unlike in metastatic disease, early breast cancer is fundamentally ER-driven. Elicestrin targets both wild-type and mutant ER, making the mutation status less critical for efficacy in this earlier setting.

Cancers with estrogen receptor (ER) expression of 50% or less, while technically HR+, often behave biologically like basal or triple-negative tumors. These cancers are not primarily endocrine-driven and show a significant benefit from the addition of immune checkpoint inhibitors, challenging traditional subtype classifications.

Despite compelling data from trials like PATINA, some patients with ER+/HER2+ breast cancer refuse maintenance endocrine therapy due to side effects. This highlights a real-world gap between clinical trial evidence and patient adherence, forcing oncologists to navigate patient preferences against optimal treatment protocols.

The innovation landscape for ER-positive metastatic breast cancer follows three parallel themes: 1) Developing superior endocrine agents like oral SERDs, 2) Advancing combination therapies with novel inhibitors (PI3K, mTOR, AKT), and 3) Creating new antibody-drug conjugates (ADCs) for patients who have become endocrine-resistant and would otherwise receive chemotherapy.

Even within recent major clinical trials like HER2CLIMB-05, less than half of eligible hormone receptor-positive patients received endocrine therapy. This highlights a critical and widespread gap in clinical practice, as this treatment adds significant benefit.

FES PET-CT relies on a tracer binding to estrogen receptors. If a patient is on ER modulators or down-regulators (like tamoxifen or fulvestrant), these drugs will block the tracer, causing a false-negative scan. Clinicians must plan for a washout period of several weeks before imaging, which requires careful treatment coordination.

Patients often worry that anti-estrogen therapies directly cause weight gain. However, the mechanism is more nuanced: the drugs induce a postmenopausal state characterized by inflammation and metabolic dysfunction, which, combined with natural aging, makes weight gain more likely and weight loss more difficult.

While the Lidera trial showed a benefit for the oral SERD giredestrant in the adjuvant setting, experts advise caution before changing practice. The trial's control arm (standard endocrine therapy) does not reflect the current standard of care for high-risk patients, which now includes CDK4/6 inhibitors, making a direct comparison difficult.

A biopsy can confirm ER-positive tissue, but FES PET-CT demonstrates that these receptors are functional and capable of binding. This distinction is critical, as some tumors may have non-functional receptors or heterogeneous expression. A positive FES scan provides strong evidence that a patient is a good candidate for endocrine therapy.